Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

ENDURANCE: Comparing KRd With VRd in Newly Diagnosed Myeloma

Initial treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) was not associated with longer progression-free survival (PFS) compared with bortezomib, lenalidomide, and dexamethasone (VRd) in...
On location

DVT Increases Health-Care Burden and Mortality in Patients with Cancer

Patients with cancer and deep vein thrombosis (DVT) experience higher rates of hospitalization and mortality, are less frequently treated with thrombolysis, and experience gastrointestinal...
On location

DREAMM-6: Evaluating Belantamab Mafodotin and Bortezomib Plus Dexamethasone in Relapsed/Refractory Myeloma

Early data from the DREAMM-6 study suggest that the combination of belantamab mafodotin, bortezomib, and dexamethasone is active in patients with relapsed or refractory...
On location

BOSTON: Weekly Combination Therapy Including Selinexor Improved PFS in Relapsed/Refractory Myeloma

Once weekly combination treatment with selinexor, bortezomib, and dexamethasone (SVd) led to an approximately 4-month improvement in progression-free survival (PFS) compared with bortezomib plus...
On location

ASPEN: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia

Treatment with the selective Bruton tyrosine kinase (BTK) inhibitor zanubrutinib resulted in a higher combined complete response (CR) and very good partial response (VGPR)...
On location

KEYNOTE-204: Pembrolizumab Superior to Brentuximab in Relapsed/Refractory Classic Hodgkin Lymphoma

Treatment with anti-PD-1 antibody pembrolizumab prolonged progression-free survival (PFS) more than brentuximab vedotin (BV) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R...
On location

Examining PTSD Symptoms in Patients Undergoing HCT

When patients undergo hematopoietic cell transplantation (HCT), they are usually hospitalized and isolated for a prolonged period and may experience a substantial physical and...
On location

Interim Results of Randomized Comparison of Ponatinib Starting Doses in Chronic-Phase CML

Response-based ponatinib dosing demonstrated clinical benefit in patients with resistant chronic-phase chronic myeloid leukemia (CML) with rate of arterial occlusive (AO) events that did...
On location

Carfilzomib-Based Quadruplet Regimen Beats Triplet Approach in Newly Diagnosed Myeloma

Induction with the quadruplet regimen of carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone (KCRD) led to deeper responses and longer progression-free survival (PFS) in patients with...
On location

Subcutaneous and Intravenous Daratumumab Have Similar Safety, Efficacy in Previously Treated and Newly Diagnosed...

A subcutaneous formulation of daratumumab, plus standard-of-care treatment, led to response rates that were similar to those seen with intravenous daratumumab in patients with...
Advertisement

Current Issue

July 2020 Volume 6 Issue 8

This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more.